Bio-Rad Laboratories (BIO-B) Accounts Payables (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Accounts Payables data on file, last reported at $133.1 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $133.1 million, down 3.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $133.1 million (down 3.48% YoY), and the FY2025 annual result was $129.0 million, up 5.48% from the prior year.
• Accounts Payables rose to $133.1 million in Q1 2026 per BIO-B's latest filing, from $129.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $161.0 million in Q1 2023 and troughed at $102.8 million in Q1 2024.
• A 5-year average of $135.6 million and a median of $135.0 million in 2022 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 36.17% in 2024, then jumped 34.21% in 2025.
• A 5-year view of Accounts Payables shows it stood at $135.0 million in 2022, then gained by 7.08% to $144.6 million in 2023, then decreased by 15.42% to $122.3 million in 2024, then increased by 5.48% to $129.0 million in 2025, then increased by 3.18% to $133.1 million in 2026.
• Business Quant data shows BIO-B's Accounts Payables at $133.1 million in Q1 2026, $129.0 million in Q4 2025, and $128.8 million in Q3 2025.